SNAP-8: the basics
What is it?
A lab-made chain of eight amino acids, built by adding two amino acids to the Argireline peptide. It is used as an ingredient in anti-wrinkle creams.
Research paper 1 ↗Research paper 2 ↗Research paper 3 ↗What do people claim it helps with?
Marketed as a stronger 'Botox-like' ingredient that softens expression lines. These claims come mainly from the company that sells the ingredient.
What has research actually shown?
No published, independent trial has tested SNAP-8 on its own in people. Two small patch studies mixed it with several other active ingredients, so its own effect is unknown.
Research paper 1 ↗Research paper 2 ↗Research paper 3 ↗Has this been demonstrated in people?
Supplier testing, laboratory ideas borrowed from the related Argireline peptide, and two small multi-ingredient microneedle-patch studies.
Research paper 1 ↗Research paper 2 ↗Research paper 3 ↗What side effects, risks and unknowns should I understand?
The patch studies reported no side effects, but they were small and short. There is little published safety data on SNAP-8 by itself.
Research paper 1 ↗Research paper 2 ↗Is it an approved medicine?
No FDA-approved medicine contains this peptide. It is a cosmetic ingredient, and FDA does not pre-approve cosmetic ingredients.
FDA safety information 1 ↗FDA safety information 2 ↗Approval here means U.S. FDA approval and applies to a particular product, formulation and use. This is a starting overview, not a complete side-effect list. Sources checked 10 October 2026; independent scientific review pending.
How is it used or studied?
Found in creams, serums and some microneedle patches. It is not an approved injection or medicine.
Different routes and formulations can have different effects. A study of one product does not validate every product with the same peptide name.
A common misunderstanding
SNAP-8 and Argireline are related but different peptides. Evidence for one does not automatically apply to the other.
What should I ask a clinician?
- What diagnosis or goal are we trying to address, and what established options are available?
- Was the expected benefit shown in people like me, using this exact product?
- How could my medicines, health conditions or pregnancy plans affect the risks?
- What monitoring is needed, and what would tell us the treatment is helping or should be stopped?
What do the research words mean?
- Peptide
- A short chain of amino acids, the building blocks of proteins.
- Preclinical
- Research in cells, tissues or animals before dependable treatment evidence in people.
- Controlled trial
- A study comparing a treatment with another treatment or a placebo to help separate its effects from other explanations.
- Biomarker
- A measurement, such as a hormone level. A change does not necessarily mean someone feels better or lives longer.
SNAP-8 Evidence & Clinical Profile
Human Study Limits
SNAP-8 has been investigated in clinical contexts. Patient outcomes must be evaluated against study size, design, and control cohorts.
Laboratory & In Vivo Assays
Cellular and animal disease models examine receptor binding affinities and signaling cascades, which require human confirmation.
What is SNAP-8?
Acetyl Octapeptide-3 is SNAP-8 is an eight-amino-acid cosmetic peptide made by extending the Argireline sequence by two amino acids. It is marketed for expression lines but has no published peer-reviewed human trial testing it on its own. Headline wrinkle-reduction figures come from the ingredient supplier. Aliases include: Acetyl Octapeptide-3, Acetyl Glutamyl Heptapeptide-3, Acetyl Octapeptide-1, Ac-EEMQRRAD-NH2.
- Sequence (one-letter)
- Ac-EEMQRRAD-NH2
- Molecular formula
- C41H70N16O16S
- Molecular weight
- 1075.2 g/mol
- CAS Number
- 868844-74-0
- UNII Code
- 8K14HJF88S
- PubChem CID
- 76283482
Identifiers checked against PubChem and FDA's Global Substance Registration System on 13 October 2026. FDA substance record ↗ · PubChem record ↗ See all names and codes in the peptide name index.
Clinical Trials & Human Cohorts
Human research can examine tolerability, symptoms or patient outcomes. The design and comparator determine what each result can establish.
Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities [2]
What was reported
The patch containing acetyl octapeptide-3 plus other actives improved eye-area wrinkles and elasticity more than the plain patch, with no adverse effects reported.
What limits the conclusion
Several active ingredients and a microneedle delivery system, so SNAP-8's own contribution is unknown. Most authors work for the patch maker.
Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study [3]
What was reported
The patch was well tolerated, and instrument measurements of fine lines, hydration and skin density improved.
What limits the conclusion
Multiple peptides and extracts in one product; no comparator described; authors affiliated with patch and testing companies.
How the compound may work
Mechanisms describe how SNAP-8 may affect biological processes. Laboratory findings and patient outcomes answer different questions.
Proposed SNAP-25 mimicry
SNAP-8 is proposed to compete with SNAP-25 and disturb SNARE complex formation, reducing neurotransmitter release in laboratory assays. The review notes that wrinkle-reduction figures come from the manufacturer's website. [1]
Parent hexapeptide
SNAP-8 extends the Argireline (Ac-EEMQRR-NH2) sequence. The parent hexapeptide interfered with SNARE complex formation in laboratory tests, far less effectively than botulinum toxin. [4]
Areas Being Studied
These research topics reflect active areas of scientific exploration, distinct from unverified commercial marketing claims.
Expression lines
Marketing claims are based on supplier testing rather than peer-reviewed, independent clinical trials of the ingredient alone. [1]
Delivery by microneedles
Dissolving microneedle patches have been tested to push peptides past the skin barrier; results cannot be credited to SNAP-8 alone. [2]
Skin penetration problem
FDA scientists found the closely related Argireline mostly stayed on or in the outer skin layer. SNAP-8 is larger, and no comparable penetration study of it was found. [5]
Compare the study designs.
| Study | Design / sample | Outcome type | Key limitation |
|---|---|---|---|
| Microneedle patch (multi-ingredient) · 2024 [2] | Comparative study, active patch on one eye area versus hyaluronic-acid-only patch on the other, 28 days n = 24 |
Clinical endpoint evaluation | Several active ingredients and a microneedle delivery system, so SNAP-8's own contribution is unknown. Most authors work for the patch maker. |
| Microneedle patch, single centre · 2020 [3] | Single-centre 12-week study of a multi-ingredient patch; no control group described in the abstract n = not stated in abstract |
Clinical endpoint evaluation | Multiple peptides and extracts in one product; no comparator described; authors affiliated with patch and testing companies. |
Regulatory Status & Clinical Safety
Regulatory Classification
United States, checked 11 October 2026: acetyl octapeptide-3 is a cosmetic ingredient, not an approved drug. FDA does not pre-approve cosmetic products or ingredients (except some color additives). Claims that a product relaxes muscles or treats a condition could make it a drug. No FDA drug approval, and no ClinicalTrials.gov record, was found for SNAP-8.
Safety Realities & Impurities
Safety depends on the molecule, formulation, route and evidence. A laboratory purity measurement alone cannot establish safety for human use.
Clinical Trials Registry Records
Official registry records from ClinicalTrials.gov. Study registration does not imply government endorsement or guaranteed efficacy.
WADA & Anti-Doping Regulations
WADA Anti-Doping Status
SNAP-8 is not prohibited under current World Anti-Doping Agency (WADA) regulations. However, athletes must ensure unregulated preparations or unverified vendor products do not violate Section S0 (Non-approved substances). Last verified: October 2026.
Research Timeline
-
2002
Parent peptide described
The Argireline hexapeptide is reported as a laboratory SNARE-complex inhibitor. [4]
-
2020
Review flags supplier data
A cosmetic-peptide review notes SNAP-8 efficacy figures come from the manufacturer. [1]
-
2024
Multi-ingredient patch study
A 24-person microneedle-patch study includes acetyl octapeptide-3 among several actives. [2]
-
2026
Still a cosmetic ingredient
No FDA drug approval; FDA does not pre-approve cosmetic ingredients. [6]
What Researchers Still Don't Know
Long-term safety profiles
Multi-year observational data in broader heterogeneous cohorts remains uncharacterized.
Optimal dose-response thresholds
Comparative trials optimizing minimal effective exposure versus adverse event rates.
Formulation bioavailability
Differences between oral, subcutaneous, and modified peptide delivery vehicles.
References
Primary sources verified against PubMed / NLM and regulatory databases.
-
Review
Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy ↗ (external website)
Full text discusses SNAP-8 sequence, proposed mechanism and that efficacy figures come from the manufacturer's website.
- Small comparative human study (multi-ingredient)
- Single-centre human study (multi-ingredient)
-
Laboratory study of parent hexapeptide
A synthetic hexapeptide (Argireline) with antiwrinkle activity ↗ (external website)
-
Laboratory skin penetration study (related peptide)
In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation ↗ (external website)
- FDA regulatory explanation
-
FDA regulatory explanation
Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) ↗ (external website)